National Laboratory of Genetics

National Laboratory of Genetics has established and applies a Quality Management System from Medical Laboratory Services in the field of Genetic Research. According to ISO 9001:2015, which is given by Munich office of the German organization TÜV SÜD, all the requirements are fulfilled.

TÜV SÜD is known internationally for the rigidity of the regulations which both company organization and product realization should meet.

National Laboratory of Genetics is the first EU and US certified and accredited private genetic laboratory in Georgia. Providing services in molecular and genetic diagnostics of human heredity diseases since 2017.

Apart from diagnostics and research, we are open for various scientific and research collaborations or projects.

The National Laboratory of Genetics meets the stringent requirements of the German TÜV SÜD, which is confirmed by the Munich Office’s laboratory certification. Our tests and processes are CE-IVD certified. The laboratory has successfully passed ISO 9001: 2015 certification. At the same time, ISO 27000 and ISO 17025 are introduced. The National Laboratory of Genetics is in the process of American CAP accreditation preparation.

Congenital deafness can be hereditary and acquired. However, 50% of congenital deafness is caused by a mutation in the GJB2 gene. Modern molecular diagnostic methods help patients plan healthy family and avoid unnecessary medication.

Optic nerve atrophy (ONA) is mostly found among middle-aged people, starting out with a significant loss of vision or even blindness. Modern molecular diagnostic methods help us predict the disease and plan correct treatment. It also aids in finding the severity of the disease that is closely linked to the identified mutations.

Phenylketonuria is a fairly common, severe but curable disease. Early diagnosis helps with deciding on special diet and preventing furter mental problems/disorders in children.

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth.

PGT-A (Preimplantation Genetic Testing for Aneuploidy) also known as PGS (Preimplantation Genetic Screening) is a genetic test that allows the determination of the chromosomal status of IVF embryos by screening all 23 pairs of human chromosomes. Only embryos with the correct number of chromosomes will be able to develop into a healthy baby. PGT-A test is able to identify those embryos free form chromosome abnormalities (euploid embryos) that are more likely to implant and result in a healthy live birth.

Preimplantation genetic testing (PGT) is the test for embryos to look for a heritable genetic mutation or chromosome abnormality, which could lead to your child having a genetic disorder or disease during childhood or later in life.

PGT for monogenic disorders (PGT-M) determines whether you have a heritable genetic mutation that can be passed on to your children.

The IONA® test is a non-invasive prenatal test for pregnant women that assesses the risk of a fetus having Down’s Syndrome (T21), Edward’s Syndrome (T18) and Patau’s Syndrome (T13). The IONA® test is an advanced screening test performed on a small blood sample taken from the mother’s arm with no risk of miscarriage.

With a thyroid tumor test, we detect 450 point mutations of 25 different genes, 25 merged genes and 3 CNVs (copy number variation). For proper diagnosis – to remove a thyroid if treatment is continued – genetic testing is needed because the cytologic (microscopic) diagnosis is not highly reliable and therefore in 20-30% of cases it is not clear.

According to the Cancer Registry, 32% of all malignancies registered in Georgia are women with breast cancer. BRCA1 and BRCA2 are known genes that cause breast and ovarian cancer.

All of us have these genes, but some people inherit one or both of these genes, which increases the risk of breast and ovarian tumors.

Spinal muscular atrophy (SMA) is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.

Most of the nerve cells that control muscles are located in the spinal cord, which accounts for the word spinal in the name of the disease. SMA is muscular because its primary effect is on muscles, which don’t receive signals from these nerve cells. Atrophy is the medical term for getting smaller, which is what generally happens to muscles when they’re not active.

SMA involves the loss of nerve cells called motor neurons in the spinal cord and is classified as a motor neuron disease.

In the most common form of SMA (chromosome 5 SMA, or SMN-related SMA), there is wide variability in age of onset, symptoms and rate of progression. In order to account for these differences, the chromosome 5 SMA often is classified into types 1 through 4.

Duchenne muscular dystrophy (DMD) is the most common fatal genetic disease diagnosed in childhood. The disease almost always affect boys, and they tend to be diagnosed before the age of 5. Duchenne muscular dystrophy is classified as a rare disease. Children born with Duchenne muscular dystrophy have a fault, known as a mutation, on their dystrophin gene, the longest gene in the body. The fault means that they cannot produce dystrophin, a protein that is vital for muscle strength and function. This lack of dystrophin results in a progressive deterioration of muscle strength and function.

National Laboratory of Genetics

Tbilisi, Georgia
240 David Agmashenebeli Alley
Tel.: +995 322 052 888


  Monday – Friday 10:00 – 17:00